The estimated Net Worth of Peter G. Piferi is at least $1.2 Million dollars as of 16 August 2021. Mr Piferi owns over 8,929 units of ClearPoint Neuro Inc stock worth over $832,331 and over the last 11 years he sold CLPT stock worth over $0. In addition, he makes $365,935 as Chief Operating Officer at ClearPoint Neuro Inc.
Mr has made over 2 trades of the ClearPoint Neuro Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 8,929 units of CLPT stock worth $30,984 on 16 August 2021.
The largest trade he's ever made was exercising 27,605 units of ClearPoint Neuro Inc stock on 23 July 2021 worth over $77,570. On average, Mr trades about 3,045 units every 2 days since 2013. As of 16 August 2021 he still owns at least 68,168 units of ClearPoint Neuro Inc stock.
You can see the complete history of Mr Piferi stock trades at the bottom of the page.
Peter G. Piferi is the Chief Operating Officer at ClearPoint Neuro Inc.
As the Chief Operating Officer of ClearPoint Neuro Inc, the total compensation of Mr Piferi at ClearPoint Neuro Inc is $365,935. There are 2 executives at ClearPoint Neuro Inc getting paid more, with Joseph Michael Burnett having the highest compensation of $596,513.
Mr Piferi is 62, he's been the Chief Operating Officer of ClearPoint Neuro Inc since . There are 1 older and 2 younger executives at ClearPoint Neuro Inc. The oldest executive at ClearPoint Neuro Inc is Dr. Paul A. Bottomley, 67, who is the Advisor.
Peter's mailing address filed with the SEC is C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE, SUITE 100, SOLANO BEACH, CA, 92075.
Over the last 12 years, insiders at ClearPoint Neuro Inc have traded over $1,109,516 worth of ClearPoint Neuro Inc stock and bought 529,405 units worth $775,964 . The most active insiders traders include Lynnette C Fallon, Michael Pietrangelo und R John Fletcher. On average, ClearPoint Neuro Inc executives and independent directors trade stock every 93 days with the average trade being worth of $207,411. The most recent stock trade was executed by Lynnette C Fallon on 14 May 2024, trading 17,153 units of CLPT stock currently worth $209,438.
we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot
ClearPoint Neuro Inc executives and other stock owners filed with the SEC include: